SoniVie is planning to begin US clinical trials of its Therapeutic Intra-Vascular Ultrasound (TIVUS) renal denervation system to treat drug-resistant hypertension in late 2021 while continuing to develop the system to also treat pulmonary hypertension.
TIVUS is a catheter-based high-frequency, non-focused ultrasound system for ablating arterial nerves. It was originally developed by Israel-based Cardiosonic for renal artery denervation to treat drug-resistant hypertension in 2009 and received a CE mark for that indication in 2014. SoniVie, founded by Accelmed Ventures in 2014, licensed TIVUS from Cardiosonic to separately develop it to treat pulmonary hypertension
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?